ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system
EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025
ALK participates at Jefferies Global Healthcare Conference 2025 in New York
ITULATEK® approved for treatment of children and adolescents in Canada
Three-month interim report (Q1) 2025 (unaudited)
ALK enters into neffy® co-promotion agreement in the USA
Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
ITULAZAX® tree pollen tablet approved for treatment of children in Europe
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
Annual General Meeting in ALK-Abelló A/S held on 13 March 2025
ACARIZAX® approved in Canada for treatment of young children
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
FDA approves ODACTRA® for the treatment of house dust mite allergy in young children
Annual General Meeting in ALK-Abelló A/S on 13 March 2025
Annual report 2024: ALK delivers 15% sales growth with profits up 65%
Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025
ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system
ALK – Financial calendar for the 2025 financial year
Positive results advance peanut tablet to phase II development
ACARIZAX® approved in Europe for treatment of young children
ALK’s pivotal phase 3 trial in children published in reputable scientific journal
Nine-month interim report (Q3) 2024 (unaudited)
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
Six-month interim report (Q2) 2024
ALK upgrades its full-year revenue and earnings outlook
Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024
ALK provides update on regulatory process for the house dust mite allergy tablet in China
ALK launches new growth strategy and 2028 financial ambitions
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review
Listen in on ALK’s Capital Markets Day on 4 June 2024
Three-month interim report (Q1) 2024 (unaudited)
ALK upgrades its full-year revenue outlook
Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024
Save the date for ALK’s Capital Markets Day on 4 June 2024
Annual General Meeting in ALK-Abelló A/S held on 14 March 2024
Annual General Meeting in ALK-Abelló A/S on 14 March 2024
Annual report 2023: ALK delivers 9% sales growth with profits up 50%
ALK and McMaster researchers discover new cell that remembers allergies
ALK’s 2030 CO2 reduction targets have been approved by SBTi
Release date of annual report 2023 for ALK and webcast
ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review
ALK completes first part of phase 1 trial with peanut SLIT-tablet
ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy
ALK – Financial calendar for the 2024 financial year
ALK expands partnership with Torii in Japan
Nine-month interim report (Q3) 2023
Release date of nine-month interim report (Q3) 2023 for ALK and audio cast
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children
Six-month interim report (Q2) 2023
Release date of six-month interim report (Q2) 2023 for ALK and audio cast
President & CEO Carsten Hellmann to step down end 2023.
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s house dust mite tablet in young children
Three-month interim report (Q1) 2023
Release date of three-month interim report (Q1) 2023 for ALK and audio cast
ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook
Annual General Meeting in ALK-Abelló A/S held on 23 March 2023
Annual General Meeting in ALK on 23 March 2023
ALK appoints Claus Steensen Sølje as new Chief Financial Officer (CFO)
Regulatory filing for house dust mite allergy tablet accepted for review in China
Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022
Release date of annual report 2022 for ALK and audio cast
Henriette Mersebach to succeed Henrik Jacobi as Executive Vice President, R&D at ALK
ALK – Financial calendar for the 2023 financial year
Management change at ALK
Nine-month interim report (Q3) 2022
Release date of nine-month interim report (Q3) 2022 for ALK and audio cast
Six-month interim report (Q2) 2022
Release date of six-month interim report (Q2) 2022 for ALK and audio cast
ALK upgrades its full-year financial outlook
ALK spotlights the impact of respiratory allergies on children at EAACI Congress
ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
Three-month interim report (Q1) 2022
Release date of three-month interim report (Q1) 2022 for ALK and audio cast
Total share capital and voting rights
Grant of share options and performance shares to members of the Board of Management and key employees
Decision to complete share split at a ratio of 1:20
Annual General Meeting in ALK-Abelló A/S held on 16 March 2022
Clinical trial waiver in China opens door to 2022 registration filing for ALK’s dust mite allergy tablet
Annual General Meeting in ALK-Abelló A/S on 16 March 2022
Annual report 2021: ALK delivers strong sales growth of 12% with tablet sales up 29% and EBITDA up 35%
